Breaking News, Collaborations & Alliances

Samsung Biologics, Kineta Enter Development and Manufacturing Agreement

Samsung's San Francisco R&D center and South Korea headquarters to offer end-to-end CDMO service for anti-VISTA antibody immunotherapy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Samsung Biologics has signed a partnership agreement with Kineta, Inc., a clinical-stage biotech company developing novel immunotherapies in oncology. Samsung Biologics will provide end-to-end CDMO service from cell line development, clinical drug substance, and drug product manufacturing services to support IND filing for KVA12.1, Kineta’s novel anti-VISTA antibody in development for the treatment of solid tumors.   VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters